SPOTLIGHT: No new adverse Tysabri events

Ten months and 10,000 patients after Tysabri was returned to the market for MS, there have been no new occurrences of the lethal infections that triggered its sudden removal in early 2005. Neurologists welcomed the news but said there was still plenty of reason to remain cautious about using the drug. Even after safety questions had been raised about Tysabri, though, many patients had remained committed to the drug due to its high efficacy rate for reducing relapses and disease progression. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.